Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 PTC Inc. (Exact name of registrant as specified in its charter) Massachusetts 04-2866152 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 121 Seaport Boulevard, Boston, MA 02210 (Address of principal executive offices, including zip code) (781) 370-5000 For the quarte ...

PTC Inc. (PTC) reported second-quarter fiscal 2025 non-GAAP earnings per share (EPS) of $1.79, beating the Zacks Consensus Estimate by 29.7%. The company reported non-GAAP EPS of $1.46 in the prior-year quarter. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Revenues came in at $636 million, rising 6% year over year (up 8% at constant currency or cc). The top line beat the consensus estimate by 4.6%. Management projected revenues in the $590-$620 million band. Despite a challenging se ...

Group 1 - PTC Inc. reported quarterly earnings of $1.79 per share, exceeding the Zacks Consensus Estimate of $1.38 per share, and up from $1.46 per share a year ago, representing an earnings surprise of 29.71% [1] - The company posted revenues of $636.37 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.62% and increasing from $603.07 million year-over-year [2] - PTC Inc. has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates three times in the same period [2] Group 2 - The stock has underperformed the market, losing about 16.4% since the beginning of the year compared to the S&P 500's decline of 5.5% [3] - The current consensus EPS estimate for the coming quarter is $1.46 on revenues of $623.14 million, and for the current fiscal year, it is $5.75 on revenues of $2.48 billion [7] - The Zacks Industry Rank for Computer - Software is in the top 31% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

PTC (PTC) Q2 2025 Earnings Call April 30, 2025 05:00 PM ET Company Participants Matt Shimao - Head, Investor RelationsNeil Barua - President & CEOKristian Talvitie - EVP & CFOAdam Borg - Managing Director - Equity ResearchRobert Dahdah - Executive Vice President, Chief Revenue OfficerSaket Kalia - Managing DirectorSiti Panigrahi - Managing DirectorJay Vleeschhouwer - Managing DirectorJoshua Tilton - Director Conference Call Participants Daniel Jester - Director & Equity Research AnalystKen Wong - Managing D ...

Financial Data and Key Metrics Changes - PTC reported a 10% year-over-year growth in Annual Recurring Revenue (ARR) and a 13% increase in free cash flow for Q2 [4][5][13] - The constant currency ARR at the end of Q2 was $2,326 million, reflecting a 10% increase year-over-year [13] - Free cash flow for Q2 was $279 million, which absorbed $3 million related to go-to-market realignment [14][16] Business Line Data and Key Metrics Changes - ARR growth was 8% in CAD, primarily driven by CREO, and 11% in PLM, driven by Windchill, CodeBeamer, and IoT [15] - The Americas saw a 9% ARR growth, Europe 11%, and Asia Pacific 10% year-over-year [15] Market Data and Key Metrics Changes - PTC's gross debt was $1,393 million, with a leverage ratio of 1.5 times [16] - The company paid down $500 million of senior notes due in February and reduced gross debt by $155 million in Q2 [16] Company Strategy and Development Direction - PTC's strategy focuses on deepening customer value through PLM, ALM, SLM, CAD, and SaaS, while leading innovation through applied generative AI [29] - The company is actively pursuing a go-to-market transformation to enhance execution and customer engagement [6][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged growing uncertainty related to global trade dynamics and macro pressures, which may affect customer buying behavior [9][10] - Despite the uncertainty, the long-term need for digital transformation remains strong, and PTC is well-positioned to support customers in this transition [12][30] Other Important Information - PTC continues to execute share buybacks under a $2 billion repurchase authorization, with $75 million used to repurchase shares in Q2 [5][16] - The company introduced several AI initiatives across its product lines, including Windchill AI and ServiceMax AI [8][53] Q&A Session Summary Question: Can you elaborate on the downside scenario for the 7% ARR growth? - Management explained that the 7% scenario considers potential delays and smaller deal sizes due to macroeconomic conditions, with a bottoms-up and tops-down assessment conducted [33][36][38] Question: What indicators show that the go-to-market changes are working? - The team reported low churn and successful execution of the vertical approach, which has improved customer engagement and pipeline quality [40][43] Question: How should investors think about the $1 billion free cash flow target next year? - Management indicated that it is premature to provide specifics, as various macroeconomic factors will influence the target [46][49] Question: How are customer discussions regarding AI adoption progressing? - Management noted increased customer engagement with AI products, emphasizing the importance of a solid product data foundation for effective AI utilization [52][54] Question: Are the conversations with customers indicating widespread deal postponements? - Management clarified that conversations vary by customer and vertical, with some customers moving forward while others may delay decisions [76][78] Question: What assumptions are behind the new ARR guidance range? - The guidance reflects a cautious outlook due to recent macroeconomic uncertainties, with the potential for improvement if trade issues are resolved [80][81]

Q2'25 FINANCIAL RESULTS Neil Barua CEO Kristian Talvitie CFO April 30, 2025 FORWARD LOOKING STATEMENTS This presentation includes forward looking statements regarding PTC's future financial performance, strategic outlook and expectations, anticipated future operations, expected effects of strategic investments and initiatives, and share repurchase expectations. Because such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Inform ...

Delivered solid execution in Q2'25 and exceeded guidance across all metrics Constant Currency ARR Growth of 10% Operating Cash Flow Growth of 12% Free Cash Flow Growth of 13% Proceeding with share repurchases under our $2 billion authorization Continuing to build a strong foundation for AI-driven and verticalized growth Updating FY'25 guidance to proactively manage macroeconomic riskBOSTON, April 30, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its second fiscal quarter en ...

Leading global automotive and industrial supplier continues product development modernization with transition to cloud-based Windchill+ PLM Windchill+ offers speed of deployment, upgrade, and collaboration benefits to help customers accelerate development time PTC and Schaeffler expect to collaborate on AI-driven product development initiatives BOSTON, April 30, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Schaeffler, a leading motion technology company, will adopt PTC's Windchill+® product ...

PTC Inc. (PTC) is scheduled to report second-quarter fiscal 2025 results on April 30, 2025, after market close.For the quarter, PTC anticipates revenues between $590 million and $620 million. Non-GAAP EPS is expected in the range of $1.30 to $1.50. The Zacks Consensus Estimate for revenues is pegged at $608.3 million, indicating an increase of 0.9% from the year-ago reported number. The consensus estimate for earnings is $1.38 per share, down 5.5% from a year ago, unchanged in the past seven days.The compan ...

- Label includes full spectrum of PKU patients -- European launch preparations underway -WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the marketing authorization application for Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The opinion includes a broad label inclusive ...